2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 741

Increased Risk of Recurrent Gout Attacks During Hospitalization
Abstract Number: 161

Increased Serum Uric Acid: Consequence or Cause of Increased Cardiovascular Risk
Abstract Number: 2292

Increased Synthesis of Leukotrienes by Peripheral Blood Mononuclear Cells Is Associated with More Severe Disease and Worse Prognosis in Patients with Systemic Sclerosis
Abstract Number: 2335

Increased TSLP Expression in Joints of Rheumatoid Arthritis Patients Causes Increased Activation of Intra-Articular Myeloid Dendritic Cells with Enhanced Th1 and Th17 Cell Activity
Abstract Number: 2062

Increasing Pneumococcal Vaccination for Immunosuppressed Patients: A Cluster Quality Improvement Trial
Abstract Number: 2633

Independence At Home: Real or Perceived
Abstract Number: 1735

Independent Validation of the Antiphospholipid Score (aPL-S) for the Diagnosis of Antiphospholipid Syndrome (APS)
Abstract Number: 2022

Individual Disease Burden in Children and Adolescents with Chronic Musculoskeletal Pain – Multilevel-Analysis of a Nationwide Prospective Longitudinal Observation Study
Abstract Number: 2549

Induction of Remission in Patients with up to 12 Months of Moderate-to-Severe Rheumatoid Arthritis Symptoms Treated with Etanercept Plus Methotrexate Over 52 Weeks
Abstract Number: L9

Inefficacy of Hydroxychoroquine in Primary Sjögren’s Syndrome: Results of the Joquer Randomized Placebo-Controlled Trial in Primary Sjögren’s Syndrome
Abstract Number: 1845

Inequalities Across 46 European Countries in Clinical Eligibility Criteria for the Start of A First (Reimbursed) Biologic in Patients with Rheumatoid Arthritis
Abstract Number: 1844

Inequities in Access to Biologic Disease-Modifying Anti-Rheumatic Drugs for Patients with Rheumatoid Arthritis Across 46 European Countries
Abstract Number: 238

Inevitable Deterioration? Trajectories and Risk Profiles of Pain in Patients with Radiographic, Symptomatic Knee Osteoarthritis
Abstract Number: 1669

Infection Risk After Orthopaedic Surgery in Patients with Inflammatory Rheumatic Diseases, with Focus On Discontinuation of TNF-Alpha-Inhibitors
Abstract Number: 1694

Infection Risk in Patients with Low Immunoglobulins Following Rituximab Treatment in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].